Identification of Lysosome‐Associated Protein Transmembrane‐4 as a Novel Therapeutic Target for Osteosarcoma Treatment

Wang, Zhexiang; Guo, Meng‐yang; Ren, Jing; Li, Gui-Shi; Sun, Xuguo

doi:10.1111/os.12692

Cited by 5 publications

(5 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to KIF11, other members of the KIF family could affect the progression and development of cancer; most of them could be potential cancer molecular targets [ 20 ]. A previous study indicated that KIF14 could contribute to the growth of hepatocellular carcinoma (HCC) [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

“…Quantitative PCR Assay. This experiment was performed according to the previous study [20]. The TRIzol reagent (15596026, Invitrogen, Carlsbad, CA, USA) was used to extract total RNA.…”

Section: 3mentioning

confidence: 99%

“…Immunoblot Assays. This experiment was performed according to the previous study [20]. Cells or tissues were lysed in RIPA Buffer (9800, Cell Signaling, MA).…”

Section: 3mentioning

confidence: 99%

See 2 more Smart Citations

KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment

Han

Chen²,

Wei³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Objective. To assess KIF11 expression in human thyroid tumor tissues and further evaluate its involvement in thyroid cancer. Methods. The expression of KIF11 in 71 cases of thyroid carcinoma as well as corresponding tissues was detected by the immunohistochemical (IHC) method. Patients were divided into the high KIF11 expression as well as low expression groups based on the staining levels. In addition, to study the relationship between the expression of KIF11 as well as clinicopathological features, the effects of KIF11 were detected on the proliferation, apoptosis, and cell cycle of two types of thyroid cancer cells, TPC-1 and KTC-1, through colony formation assays, MTT assays, and FCM assays, respectively. We further assessed the potential effects of KIF11 on tumor growth using an animal model. Results. The significantly high expression of KIF11 in thyroid tumor tissues was revealed, and the correlations between KIF11 expression levels as well as clinical pathological features (T stage and intraglandular dissemination) of patients were revealed. We further noticed that KIF11 knockdown remarkably suppressed thyroid cancer cell proliferation as well as induced cell apoptosis of thyroid cancer cells. Additionally, KIF11 contributed to tumor growth of thyroid cancer cells in mice. Conclusions. We noticed the involvement of KIF11 in the progression of thyroid cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Quantitative PCR Assay. This experiment was performed according to the previous study [20]. The TRIzol reagent (15596026, Invitrogen, Carlsbad, CA, USA) was used to extract total RNA.…”

Section: 3mentioning

confidence: 99%

See 1 more Smart Citation

KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment

Han

Chen²,

Wei³

et al. 2022

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Recently, we identified that LAPTM4B promotes integrin beta1 recycling and focal adhesion dynamics, critical progress promoting skin cancer development [ 24 ]. However, LAPTM4B has not been well investigated in OS hitherto, albeit two pilot studies suggest the high expression of LAPTM4B in OS [ 25 , 26 ]. The detailed mechanism underpinning LAPTM4B dysregulation in OS is not recognized, besides, the functional phenotype and relevant mechanisms remain unknown.…”

Section: Introductionmentioning

confidence: 99%

miR-137–LAPTM4B regulates cytoskeleton organization and cancer metastasis via the RhoA-LIMK-Cofilin pathway in osteosarcoma

et al. 2023

View full text Add to dashboard Cite

Osteosarcoma (OS) is a rare malignant bone tumor but is one leading cause of cancer mortality in childhood and adolescence. Cancer metastasis accounts for the primary reason for treatment failure in OS patients. The dynamic organization of the cytoskeleton is fundamental for cell motility, migration, and cancer metastasis. Lysosome Associated Protein Transmembrane 4B (LAPTM4B) is an oncogene participating in various biological progress central to cancer biogenesis. However, the potential roles of LAPTM4B in OS and the related mechanisms remain unknown. Here, we established the elevated LAPTM4B expression in OS, and it is essential in regulating stress fiber organization through RhoA–LIMK–cofilin signaling pathway. In terms of mechanism, our data revealed that LAPTM4B promotes RhoA protein stability by suppressing the ubiquitin-mediated proteasome degradation pathway. Moreover, our data show that miR-137, rather than gene copy number and methylation status, contributes to the upregulation of LAPTM4B in OS. We report that miR-137 is capable of regulating stress fiber arrangement, OS cell migration, and metastasis via targeting LAPTM4B. Combining results from cells, patients’ tissue samples, the animal model, and cancer databases, this study further suggests that the miR-137–LAPTM4B axis represents a clinically relevant pathway in OS progression and a viable target for novel therapeutics.

show abstract

“…Figure 3d has the same images used in Figure 3d by Wang et al [3]. , figure 3b in Wang et al [4]. , and figure 3d by Chen & Zhong [5].…”

mentioning

confidence: 99%

APLNR promotes the progression of osteosarcoma by stimulating cell proliferation and invasion: Retraction

2023

Anti-Cancer Drugs

View full text Add to dashboard Cite

Identification of Lysosome‐Associated Protein Transmembrane‐4 as a Novel Therapeutic Target for Osteosarcoma Treatment

Cited by 5 publications

References 29 publications

KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment

KIF11 Is a Promising Therapeutic Target for Thyroid Cancer Treatment

miR-137–LAPTM4B regulates cytoskeleton organization and cancer metastasis via the RhoA-LIMK-Cofilin pathway in osteosarcoma

APLNR promotes the progression of osteosarcoma by stimulating cell proliferation and invasion: Retraction

Contact Info

Product

Resources

About